|
|
Unless you were hanging out under a rock yesterday 🪨, you heard the great news that, once again, the CPI report came in line with expectations. 📉 |
I think inflation is firmly under control now (in fact, deflation might be the new buzzword in 2024), and it is only a matter of time before the Fed starts to cut rates again. |
The market is front-running that event, and that has been driving stock prices higher, as you have seen in the last few weeks. |
On days like today, I prefer not to hinge my bets on Powell's every word and try to chase large-cap tech stocks (which are already in nosebleed territory) higher. |
Instead, I look for smaller stocks that are less sensitive to his whims. |
Right now, I have one in my sights that I think has the potential for an outsized move in the very near future. |
If you are looking for an incredible opportunity right now, then you need to pull up this ticker on your platform immediately: |
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) |
Coeptis is a clinical-stage biopharma company based in Wexford, PA, that's set out on a very bold mission to revolutionize cancer therapy. |
Fun fact: I was an early investor in COEP, prior to when they listed on the Nasdaq earlier this year. |
I am very familiar with this company, and I think right now is an ideal time for you to take a look at this if you haven't before. |
The stock has a history of powerful swings, including a 33% jump in two weeks early last month, and then another 15% rally just after that. |
It's drawn back since then, but what's happened over the last week is what interests me most… |
As you can see here, the stock refuses to drop beneath a $1.00 floor and has traded ultimately sideways. |
|
If you've followed me for any time at all, you know I love this setup. |
It's a strong hint that the bottom is in and that we could be looking at a serious upswing in the near term. |
And if the analysts are right. That swing could be very dramatic. |
Just look at how fast the reversals have been. |
That is why I think it is imperative you get COEP on your radar right away. |
Let's dig into what COEP is up to. |
Pioneering cancer therapies |
At the core of COEP's pipeline is an attempt to pioneer new treatments for cancer using cell therapy. |
According to trusty-old Wikipedia, cell therapy is: |
a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T-cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy, or grafting stem cells to regenerate diseased tissues. |
|
|
These cutting-edge treatments are potentially very lucrative. |
Precedence Research has stated: "The global cell therapy market was valued at US $10.35 billion in 2021, and it is expected to hit US $60.67 billion by 2030." |
For the numerically challenged, that's a nearly 500% increase in less than a decade. |
From a business standpoint, COEP is certainly barking up the right tree. |
One of the core technologies the company hopes to tap those billions with is known as SNAP-CAR. |
Universal SNAP-CAR Platform |
COEP licensed and acquired SNAP-CAR from the University of Pittsburgh in 2022. |
It's a fascinating technology that has the potential to revolutionize cancer treatment. |
The "CAR" part of the name refers to "chimeric antigen receptor" T-cell therapy, which is a relatively new cancer treatment that genetically engineers immune cells to target and destroy cancer cells. You can read more about CAR-T therapy here. |
Currently approved CAR-T therapies are useful against blood cancers but not so much in solid tumors. |
COEP believes its SNAP-CAR technology will improve on those existing therapies in several ways. |
Here are the basics of how it works: |
|
With SNAP-CAR, if a patient presents with cancer, an oncologist will be able to administer a "universal" CAR-T cell, which is already ready to go. |
Current CAR-T therapies require cells to be pulled from the patient or a donor, modified, and then readministered to the patient — a difficult and expensive process. |
If SNAP-CAR works the way the company hopes it will, oncologists will be able to use the same "universal" cell to attack many different cancers at multiple points along the cancer cells. |
This last part is important because it could head off cancer's ability to mutate and evolve away from a single line of attack. |
Oncologists would also be able to control the dose of each antibody, which could reduce side effects and boost the immune response. |
So far, the SNAP-CAR has shown effectiveness in three different mouse models, including one of a solid tumor. |
Clinical trials will have to bear this out, but if SNAP-CAR proves effective even against solid tumors, that would distinguish it from existing CAR-T therapies and dramatically broaden the range of cancers it could fight. |
At the core of the SNAP-CAR technology is the use of stem cells to "universalize" the therapy. It's for that reason that in August, COEP licensed "an allogeneic stem cell expansion and differentiation platform." |
Cord-Blood-Derived Stem Cell Platform |
When COEP licensed the stem-cell expansion platform, along with it came Dr. Colleen Delaney, who invented the platform. She's now Coeptis' chief scientific and medical officer. |
I'll be honest, I normally don't find biology that fascinating, and I generally dive into it only when investigating biopharma companies, but I found this interview with Dr. Delaney fascinating, and I highly recommend reading through it to see what COEP is up to. |
Here's the "Cliffs Notes" version:
Umbilical-cord-derived stem cells are cheap and prevalent. As she says, "It's medical waste. This is stuff that's thrown away every single day, so the supply chain is always going to be there." |
As mentioned above, existing CAR-T therapies rely on cells pulled from the patient's body. The problem is that "[t]hese patients' extensive history with multiple rounds of chemotherapy and lymphodepletion makes harvesting healthy, viable cells a challenge." |
By contrast, "Cord blood is the youngest, healthiest, fully regulated source of cells." |
By licensing this stem-cell expansion and differentiation platform, COEP has effectively "in-housed" this important part of the SNAP-CAR approach to cell therapy. |
Sorry for nerding out on you there 🤓, but again, I found it fascinating. |
Wrapping Up |
COEP is a small biopharma company looking to tap into a market projected to climb higher than $60B by 2030. |
I've only skimmed over two of its core technologies, but you can read about those and more at the company's website here. |
I think the stock is very attractive at this level. It has tested $1 a few times, and then witnessed a major bounce every single time (so far). |
Will it be another 33% move — or better — like it made just last month? I'm no oracle, but if you go and study COEP's chart (which you should!), you'll see the stock is no stranger to moves like that. |
In the longer term, analysts see a lot of upside for COEP, with the price targets of $3.00 and $4.00 representing multiples of its current price: |
|
As always, make sure you enter every trade you make with a solid understanding of the risk you are taking and only enter trades that you have a good risk-defined strategy. |
I'd also strongly recommend that you watch the COEP investor presentation from last week. It is an excellent review of the company. |
In the meantime, happy "Fed Day"! |
Let's hope Powell doesn't dump coal in our stockings later this afternoon… |
To Your Success, |
|
*This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
Questions or concerns about our products? Email Support@ragingbull.com |
© Copyright 2023, RagingBull |
|
Disclaimer | *ISSUE-PAID ADVERTISEMENT. RagingBull has currently been paid fifteen thousand dollars by ach bank transfer by Coeptis Therapeutics Holdings, Inc from a period beginning on December 13, 2023 through December 15 of the same year. Previously, RagingBull was paid nineteen thousand dollars by ach bank transfer by Lifewater Media for advertising Coeptis from a period beginning on June 7, 2023 through June 8 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in Coeptis Therapeutics Holdings, Inc. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Coeptis Therapeutics Holdings, Inc, increased trading volume, and possibly an increased share price of the Coeptis Therapeutics Holdings, Inc securities, which may or may not be temporary and decrease once the marketing arrangement has ended. | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company's financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. | SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. | Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull's business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. | NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," "expects," "projects," "intends," or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www. sec. gov/edgar /searchedgar /company search | TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. |
|
|
|
No comments:
Post a Comment